Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1☆
Introduction
Chemokines are a group of small proteins that play an important role in recruiting leukocytes during inflammatory and immune responses. The biological effects of chemokines are produced by interacting with specific G protein coupled receptors on target cells. To date, a total of 18 chemokine receptors, including 11 CC, five CXC, one CX3C, and one C chemokine receptor, have been identified [1]. Chemokines are involved in a number of diseases, ranging from HIV-1 infection and tumor growth to acute and chronic inflammation. Discovery and design of chemokine inhibitors and antagonists may yield drugs with significant therapeutic benefit [2].
In an effort to find naturally occurring chemokine antagonists, we screened a number of Chinese herbal medicinal components for activity. Zicao [purple gromwell, the dried root of Lithospermum erythrorhizon Sieb. et Zucc, Arnebia euchroma (Royle) Johnst. and Arnebia guttata Bunge.], is believed to possess the properties of removing heat from the blood and detoxicating, and have been used in China for thousands of years to treat macular eruption, measles, sore-throat, carbuncle and burn [3]. The major active components of Zicao have been identified as shikonin and its derivatives [4]. These chemically characterized components from Zicao have been reported to possess multiple biological properties including anti-inflammatory effects [5], [6], [7], [8], [9].
In this study, we found that shikonin selectively blocked radiolabelled regulated on activation, normal T cell expressed and secreted (RANTES) and macrophage inflammatory protein-1 (MIP-1α) binding to human monocytes, but did not block stromal cell-derived factor-1 (SDF-1α) binding. We further showed that shikonin specifically blocked radiolabelled chemokine binding to cells stably transfected with CC chemokine receptor-1 (CCR1), but did not inhibit ligand binding to CCR2, CCR3, CCR5, CXCR3 or CXCR4 transfected cells. Additionally, shikonin inhibited CCR1 cell migration induced by RANTES, but did not inhibit epidermal growth factor (EGF)-induced migration.
Section snippets
Reagents and cells
Shikonin (Fig. 1) was obtained from TCI (Tokyo, Japan). 125I-labelled RANTES, MIP-1β, monocyte chemoattractant protein-1 (MCP-1), SDF-1α, eotaxin, and interferon-inducible T cell α-chemoattractant (I-TAC) were purchased from Dupont NEN (Boston, MA); EGF was from peprotech (Rocky Hill, NJ). Human blood enriched in mononuclear cells was obtained from normal donors by leukapheresis (Transfusion Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, under approved human
Effect of shikonin on binding of chemokines to human monocytes
In our study of anti-inflammatory compounds from traditional Chinese medicine, we discovered that shikonin significantly blocked 125I RANTES binding to monocytic cell line THP-1; however, this compound failed to inhibit 125I SDF-1α binding, even up to 3.46×10−4 M (100 μg/ml) (data not shown). Shikonin also inhibited binding of RANTES and MIP-1α to human monocytes in a dose-dependent manner; the observed IC50 were 3.58×10−6 and 2.57×10−6 M, respectively (Fig. 2A and B). At concentrations over
Discussion
This report shows that shikonin selectively inhibits RANTES and MIP-1α, two high affinity ligands for CCR1, binding to THP-1 cells, human monocytes and CCR1-expressing cells. The most likely mechanism of shikonin's action is direct interaction with the CCR1 receptor. Shikonin was unable to inhibit MCP-1 binding to CCR2 cells, eotaxin binding to CCR3 cells, I-TAC binding to CXCR3 cells and SDF-1α binding to CXCR4 cells. Additionally, shikonin only inhibited RANTES-induced CCR1 cell migration,
Acknowledgements
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, and Alternative Medicine Program of National Institutes of Health, under Contract no. Y2-AT-9002.
References (24)
- et al.
Impairment of phosphatidylinositol signaling in acetylshikonin-treated neutrophils
Biochem. Pharmacol.
(1997) - et al.
A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration
J. Immunol. Methods
(1980) EGF receptor
Int. J. Biochem. Cell. Biol.
(1999)- et al.
Expression of type V adenylyl cyclase is required for epidermal growth factor-mediated stimulation of cAMP accumulation
J. Biol. Chem.
(1995) - et al.
Interfering with chemokine networks—the hope for new therapeutics
Curr. Opin. Chem. Biol.
(1999) - et al.
Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor
J. Biol. Chem.
(1998) - et al.
Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1
J. Biol. Chem.
(2000) - et al.
Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor
Eur. J. Pharmacol.
(2000) - et al.
Identification of a non-peptidic RANTES antagonist
Bioorg. Med. Chem. Lett.
(1998) - et al.
A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
J. Biol. Chem.
(2000)
Opportunities for novel therapeutic agents acting at chemokine receptors
Drug Discovery Today
International union of pharmacology: XXII. Nomenclature for chemokine receptors
Pharmacol. Rev.
Cited by (0)
- ☆
The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organization imply endorsement by the U.S. Government.